Maggot Therapy for Wound Debridement
MAGGOT
1 other identifier
interventional
120
1 country
3
Brief Summary
The main objective of the trial was to study the efficacy of bagged larvae on wound debridement in comparison to classical treatments. The secondary outcome was to assess wound healing, treatment related pain, microbiological modifications, adverse events, comfort of the dressing and duration of wound care. We performed a randomized, double-blind, multicenter, controlled, prospective phase III trial in three referral institutional centers of hospitalized care in Caen, Lisieux and Lyon, France. A total of 120 patients with a non-healing fibrinous wound ≤ 40cm2, less than 2cm-deep, and an ankle-brachial pressure index (ABPI) ≥ 0.8 were included, from March 2005 to December 2008. During two weeks´ hospitalization, patients received either Maggot Debridement Therapy (MDT, changes of bagged larvae twice a week) or classical treatments (mechanical debridement and classical dressings performed three times a week). At discharge, classical dressings were applied and a follow-up visit performed at D30. Main outcome measure was the comparison of the reduction of fibrin percentage on wounds treated with MDT and classical treatments at D15. The percentages of fibrin were measured using a computerized planimetry software package, Canvas (ACD Systems, British Columbia, Canada), which enables the quantification of color surface variations in a wound after manual delimitation (using a mouse) on a series of photographic images.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2006
CompletedFirst Submitted
Initial submission to the registry
September 28, 2010
CompletedFirst Posted
Study publicly available on registry
September 29, 2010
CompletedSeptember 29, 2010
September 1, 2010
September 28, 2010
September 28, 2010
Conditions
Outcome Measures
Primary Outcomes (1)
Percent of Fibrin changes from day 0 to day 15
Secondary Outcomes (1)
Percent of healing changes from day 0 to day 15
Study Arms (2)
Maggot Debridement Therapy
EXPERIMENTALcontrol
ACTIVE COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- patient between 18 and 90 years old
- patients with a non-healing fibrinous wound ≤ 40cm2 (pressure ulcer or venous ulcers
- pressure ulcers were less than 2cm-deep
- limb wounds were venous ulcers with an ankle-brachial pressure (ABP)≥ 0.8
- signed informed consent
You may not qualify if:
- patients pregnant or lactating
- patients with neuropathy
- patients perforant ulcer of the foot
- patients with dementia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital, Caenlead
- Société de Dermatologie Françaisecollaborator
Study Sites (3)
Hospital of Caen, dermatology department
Caen, Calvados, 14000, France
Robert Bisson Hospital
Lisieux, Calvados, 14107, France
Hopital des armées Desgenettes
Lyon, Rhone, 69000, France
Related Publications (1)
Opletalova K, Blaizot X, Mourgeon B, Chene Y, Creveuil C, Combemale P, Laplaud AL, Sohyer-Lebreuilly I, Dompmartin A. Maggot therapy for wound debridement: a randomized multicenter trial. Arch Dermatol. 2012 Apr;148(4):432-8. doi: 10.1001/archdermatol.2011.1895. Epub 2011 Dec 19.
PMID: 22184720DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 28, 2010
First Posted
September 29, 2010
Study Start
February 1, 2006
Last Updated
September 29, 2010
Record last verified: 2010-09